IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Mexico biopharmaceutical packaging market. The Mexico biopharmaceutical packaging market size reached USD 342.3 Million in 2025 and is projected to reach USD 724.8 Million by 2034, exhibiting a CAGR of 8.43% during 2026-2034. Growth is propelled by the expanding pharmaceutical industry, rising production of vaccines and biologics, innovation in drug delivery systems such as prefilled syringes and autoinjectors, growing demand for generic drugs, and the shift toward sustainable, eco-friendly packaging materials.

Mexico is moving from being a large consumer of medicines to a manufacturing base for them. Under Plan México, pharmaceutical companies announced investments of more than MXN 21 billion (about USD 1.2 billion) in May 2026 to raise domestic output of medicines, vaccines, and medical devices, while the federal health regulator COFEPRIS reduced clinical trial approval times from 120 to 30 days. Every injectable, vaccine, and biologic produced under this build-out needs sterile, validated primary containers, closures, and traceable secondary packaging. That makes packaging a strategic enabler of Mexico's biologics ambitions, and it explains why the market is projected to more than double by 2034.

Mexico Biopharmaceutical Packaging Market at a Glance:

•        Market Size (2025): USD 342.3 Million

•        Forecast Market Size (2034): USD 724.8 Million

•        CAGR (2026-2034): 8.43%

•        Key Demand Driver: Rising production of vaccines and biologics, which requires advanced packaging that protects product integrity and meets stringent regulatory standards

•        Key Trend: Prefilled syringes and single-dose formats, sustainable and recyclable materials, and smart labeling with track-and-trace functionality

•        Key Opportunity: Personalized medicine, biologics expansion, and green packaging innovation, positioning Mexico as a strategic packaging location in Latin America

•        Key Challenge: High regulatory compliance costs, large investments in sterile packaging, and complex supply chains

•        Key Industrial Hub: The State of Mexico, which accounts for 19.1% of the country's chemical-pharmaceutical economic units, alongside Mexico City, Querétaro, and Monterrey

How AI is Reshaping the Future of the Mexico Biopharmaceutical Packaging Market

•        AI-Powered Visual Inspection for Injectables: Injectable products in vials, ampoules, cartridges, and syringes require 100% visual inspection for particles and cosmetic defects. Stevanato Group, which operates a glass packaging plant in Monterrey, Nuevo León, offers inspection platforms such as MAVIS, and its cloud-based Vision AI platform is reported to cut false rejects roughly tenfold, helping manufacturers avoid quarantining good product.

•        Multi-Format, AI-Ready Inspection Lines: Equipment such as Koerber's Switch 75, which inspects vials and syringes on a single machine, and the Dabrico DAI-50, which uses unsupervised AI for vials, syringes, and ampoules with recipe setup in under 60 minutes, were highlighted in a March 2026 vendor evaluation. Flexible lines like these suit contract manufacturers and plants in Mexico that run several container formats for domestic and export markets.

•        Growing AI Adoption in Pharma Quality Control: A 2024 global survey found that nearly 70% of pharmaceutical companies use AI in at least some capacity, and regulators are developing assessment frameworks for AI used in drug manufacturing, including visual inspection. For export-oriented Mexican plants that must satisfy FDA-aligned quality expectations, AI-supported inspection and traceability are becoming part of the packaging value proposition.

Grab a sample PDF of this report: https://www.imarcgroup.com/mexico-biopharmaceutical-packaging-market/requestsample

Mexico Biopharmaceutical Packaging Market Trends and Drivers:

The core demand driver for the Mexico biopharmaceutical packaging market is the build-up of local biologics and vaccine manufacturing. In August 2025, the government announced more than MXN 12 billion (USD 643.4 million) in new pharmaceutical investments, including a MXN 3.5 billion pharmaceutical and biotech plant planned by AstraZeneca's Carnot Laboratorios in Hidalgo for exports to over 30 countries. In May 2026, Laboratorios Liomont committed more than MXN 4 billion over five years, covering an expanded injectables plant for biotechnology medicines and vaccines, a recombinant vaccine facility, and a messenger RNA synthesis and encapsulation plant. Each of these projects increases demand for vials, syringes, cartridges, closures, and cold-chain-ready secondary packaging.

The market's structural differentiator is the shift toward patient-centric, convenience-led formats. Prefilled syringes and single-dose vials are gaining traction for injectables and biologics because they reduce contamination risk and support self-administration and home care, and companies are adding tamper-evident and child-resistant features. Suppliers are investing locally to serve this demand. Gerresheimer is expanding its Querétaro plant with 10 glass forming machines to raise capacity for ready-to-fill syringes suitable for biopharmaceuticals, Stevanato Group has doubled its Monterrey glass plant, and Schott runs a pharmaceutical packaging hub in Córdoba, Veracruz that supplies ampoules, vials, and cartridges across North and Central America. Smart packaging with QR codes, RFID tags, and embedded sensors is also spreading, improving traceability, anti-counterfeiting, and monitoring of temperature-sensitive products.

Sustainability and regulation form the third pillar. Envases Universales de México reported that 98.2% of its plastic packaging was recyclable or compostable as of 2020 and launched Mexico's largest PET bottle-to-bottle recycling facility in 2021 with a 60,000-ton annual capacity, while global suppliers such as Aluflexpack have introduced fully recyclable aluminium blister packs for pharma. At the same time, packaging must comply with NOM-059-SSA1-2015 for good manufacturing practices and NOM-072-SSA1-2012 for labeling, and COFEPRIS can now consider evaluations by agencies such as the FDA, EMA, and MHRA. Compliance costs, sterile packaging investment, and complex supply chains remain the main challenges, but they also favor suppliers with validated, scalable capacity.

Ask an analyst for customized report: https://www.imarcgroup.com/request?type=report&id=34890&flag=E

Government Schemes and Regulatory Initiatives Driving Demand:

•        Plan México Pharmaceutical Decree: Announced by President Claudia Sheinbaum in May 2025, the decree is designed to attract international pharmaceutical investment and localize production, giving companies that manufacture in Mexico advantages in government procurement tenders. The stated objective of Plan México is to produce more in Mexico than the country consumes and to diversify exports beyond the United States, which directly supports demand for locally sourced pharmaceutical packaging.

•        COFEPRIS Regulatory Modernization: COFEPRIS confirmed at the Scientific Conference 2026 that it cut clinical trial approval times from 120 to 30 days, and a Permanent Interinstitutional Board for Clinical Protocols has operated since January 2026 with the National Center for Research and Health Evaluation and the National Commission of Bioethics. Faster approvals shorten the path from clinical studies to commercial supply, pulling packaging demand forward.

•        NOM-059-SSA1-2015 and NOM-072-SSA1-2012: NOM-059 sets good manufacturing and storage practices for medicines, while NOM-072 governs labeling and conservation requirements. COFEPRIS-compliant artwork must also meet barcode and serialization standards as track-and-trace frameworks expand, which raises the technical specification of printed and smart packaging.

•        Biotechnological and Biosimilar Medicines Framework: COFEPRIS modified NOM-059 in 2023 to ease access to high-quality biotechnological and biosimilar medicines, as part of a Regulatory Certainty Strategy that also promotes domestic manufacturing of these products. Larger biologics and biosimilars pipelines require specialized sterile primary packaging such as prefilled syringes and glass vials.

Mexico Biopharmaceutical Packaging Market Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Material:

•        Plastic

•        Paper

•        Glass

•        Aluminum

Breakup By Packaging Type:

•        Vials

•        Bottles

•        Ampoules

•        Syringes

•        Cartridges

Breakup By Application:

•        Vaccines

•        Monoclonal Antibodies

•        Gene Therapies

•        Cell-based Therapies

•        Cytokines

•        Others

Breakup By Region:

•        Northern Mexico

•        Central Mexico

•        Southern Mexico

•        Others

Competitive Landscape:

The Mexico biopharmaceutical packaging market features intense competition among multinational and local companies across sterile containers, blister packs, and flexible packaging. Key players active in or supplying the Mexican market include:

•        Gerresheimer

•        SCHOTT

•        Stevanato Group

•        West Pharmaceutical Services

•        Amcor

•        Aptar Group

•        Envases Universales de México

•        Aluflexpack

Gerresheimer, Schott, and Stevanato Group have manufacturing sites in Querétaro, Córdoba, and Monterrey respectively, giving them proximity to Mexican drug makers and to North American customers. Envases Universales de México is a local leader in plastic packaging and recycling, and Aluflexpack has launched recyclable aluminium pharma blisters. Strategic alliances with pharmaceutical manufacturers and investments in new technology are improving efficiency and strengthening positioning in biosimilars packaging. The report also covers market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant.

What Does The Full Report Cover?

•        Historical market performance from 2020-2025 and forecasts for 2026-2034, with market size in Million USD

•        Detailed analysis by material, covering plastic, paper, glass, and aluminum

•        Packaging type analysis across vials, bottles, ampoules, syringes, and cartridges

•        Application analysis across vaccines, monoclonal antibodies, gene therapies, cell-based therapies, cytokines, and others

•        Regional analysis of Northern Mexico, Central Mexico, Southern Mexico, and others

•        Industry catalysts and challenges, and Porter's Five Forces analysis

•        Competitive landscape with market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant

Recent News and Developments in Mexico Biopharmaceutical Packaging Market

•        August 2025: The Mexican government announced more than MXN 12 billion (USD 643.4 million) in new pharmaceutical investments, including Boehringer Ingelheim's MXN 3.5 billion expansion in Xochimilco, Bayer's MXN 3 billion plan, and a MXN 3.5 billion pharmaceutical and biotech plant by AstraZeneca's Carnot Laboratorios in Hidalgo, expected to create thousands of direct and indirect jobs.

•        January 2026: SCHOTT Pharma expanded its specialty vial portfolio for sensitive biologic drugs, reflecting rising demand for high-performance primary containers for biologics.

•        February 2026: Moderna and Laboratorios Liomont signed a memorandum to expand domestic production of messenger RNA vaccines, including a phased plan to install an mRNA vaccine manufacturing plant in Mexico through gradual technology transfer.

•        May 2026: President Sheinbaum highlighted pharmaceutical industry investment of more than MXN 21 billion (USD 1.2 billion) under Plan México, with plans presented by companies including Abbott, Bristol Myers Squibb, Grupo Neolpharma, Laboratorios Kener, Laboratorios Liomont, Vazol Farma, Sanofi, Opella, and Bayer, covering medicines, vaccines, and medical devices.

•        May 2026: Laboratorios Liomont announced an investment of more than MXN 4 billion over five years, including an expanded injectables plant for biotechnology medicines and vaccines, an expanded biopharmaceutical and recombinant vaccine plant in Mexico City, and a new mRNA synthesis and encapsulation plant.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

Key Questions This Report Answers

•        How has the Mexico biopharmaceutical packaging market performed so far, and how will it perform in the coming years?

•        What is the breakup of the Mexico biopharmaceutical packaging market on the basis of material?

•        What is the breakup of the market on the basis of packaging type, including vials, syringes, and cartridges?

•        What is the breakup of the market on the basis of application, including vaccines and monoclonal antibodies?

•        Which regions of Mexico offer the strongest growth opportunities for biopharmaceutical packaging suppliers?

•        What are the key driving factors, challenges, and opportunities in the Mexico biopharmaceutical packaging market?

•        What is the structure of the market, who are the key players, and what is the degree of competition?

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: [email protected]

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104